27 September 2016 - The company that is bringing the gold standard in abortion drugs to Canada says it is “open” to re-entering a review process that could lead to provincial drug plans reimbursing women for the $300 cost of the medication.

But Celopharma Inc. signalled it would need some sort of fee reduction or forgiveness from the independent body that assesses the cost effectiveness of new drugs because of the “significant” financial risk the fledgling company has already shouldered in its quest to make Mifegymiso available in this country.

Read Globe and Mail article